The Latest Breaking News from Illumina

Illumina shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

A Relative Strength Rating upgrade for Illumina shows improving technical performance.

Illumina is expected to release its second-quarter earnings next month, analysts expect a double-digit earnings dip.

With the rising investment in personalized medicine research and development and growing clinical trials, the biopharma industry’s prospects appear promising. Hence, quality biotech stocks, Alnylam Pharmaceuticals (ALNY), Illumina (ILMN), and Gilead Sciences (GILD) with long-term growth might be solid buys. Read more….

CrowdStrike, KKR and GoDaddy will join the index before the open on June 24, as part of the quarterly rebalance.

The biotech industry is well poised to flourish, buoyed by its strong emphasis on technology-driven advancements to address complex medical challenges and government funding. Hence, quality biotech stocks Harmony Biosciences Holdings (HRMY), Illumina (ILMN), and Compugen (CGEN) could be ideal watchlist additions for May. Read more….

Illumina announces CFO transition as Mr. Goswami departs and Mr. Dhingra steps in to lead the company's financial management.

The biotech industry is expected to grow rapidly due to rising demand for tailored treatments, increased R&D spending, and technological advancements. Therefore, fundamentally strong biotech stocks Harmony Biosciences Holdings (HRMY), Illumina (ILMN), and Halozyme Therapeutics (HALO) could be worth adding to your portfolio. Read on.

Legal battle between GRAIL-M-A-ILLUMINA-EU and Illumina over merger powers may reshape industry landscape and set new precedents.

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.90%. Stocks this morning extended Wednesday’s rally, with the S&P 500, Dow Jones Industrials,...

The biotech industry’s growth prospects look promising due to innovative drugs and therapies, government initiatives, and technological advancements. Therefore, investors could consider buying fundamentally strong biotech stocks BioMarin Pharmaceutical (BMRN), Illumina (ILMN), and Harmony Biosciences (HRMY). These stocks are B-rated (Buy) in our proprietary rating system. Read on.